Julia Castillo González: Role of Cortistatin During the Acute and Subacute Phases of Ischemic Stroke
Julia Castillo González, Early-career researcher at CHUV, shared a post on LinkedIn about a recent article she and her colleagues co-authored, published in Journal of Biomedical Science, adding:
“We are thrilled to share our latest paper, just published in the Journal of Biomedical Science!
Ischemic stroke remains a leading cause of death and disability worldwide.
Neuroinflammation and blood-brain barrier disruption play a critical role in neuronal damage.
Therefore, understanding which endogenous factors control these processes is vital for developing new therapies.
In our study, we explored the role of cortistatin, a neuropeptide with potent immunomodulatory actions, during the acute and subacute phases of ischemic stroke.
What are our key findings?
Without cortistatin, the damage worsens:
We demonstrate for the first time that a deficiency in this neuropeptide amplifies neuroinflammation, worsens glial and neurovascular dysfunction, and even accelerates aging-associated pathological features.
Therapeutic potential:
Conversely, administering cortistatin improves neuronal survival, mitigates immune dysfunction, and preserves both myelin and vascular integrity.
These results highlight cortistatin not only as an essential neuroimmune regulator but also as a highly promising multimodal therapeutic agent for improving short- and long-term stroke outcomes.
None of this would have been possible without the incredible work and dedication of the entire team and my co-authors.
Thank you all for the hard work!
On a very personal note, this work represents the third and final chapter of my PhD thesis.
I am incredibly happy and proud to close this cycle!”
Title: Lack of cortistatin drives neuroimmune and vascular dysfunction in brain ischemia
Authors: Julia Castillo-González, Pablo Vargas-Rodríguez, Ignacio Serrano-Martínez, Alejandro Cuenca-Martagón, Irene Forte-Lago, Melanie Price, Lara Buscemi, Lorenz Hirt, José Luis Ruiz, Elena González-Rey
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 30, 2026, 03:06Salvatore Brugaletta: Is Twelve Months of DAPT Still Too Long After ACS?
-
Jun 30, 2026, 02:55Edward Lee Carter: How A Landmark Stewardship Shift Reduced Unnecessary Antiplatelet Use Across VISN 8
-
Jun 30, 2026, 02:43Nicolas Gendron: More than a Research Fellowship – Leaving the Wagner Lab
-
Jun 30, 2026, 02:29Wolfgang Miesbach: Can We ‘Pre‑Tame’ the Immune System to Unlock Better AAV8 FVIII Expression?
-
Jun 30, 2026, 02:21Mohammad Khalil: Evaluating DAPT Duration after Percutaneous Coronary Intervention
-
Jun 30, 2026, 02:11Rishdha Roshad: Activated Clotting Time – Adult vs Pediatric
-
Jun 29, 2026, 23:26Sandy Middleton: The 2026 Stroke Clinical Care Standard Has Arrived with Nursing Leadership at Its Core
-
Jun 29, 2026, 22:14To Continue or Interrupt DOAC Therapy? The Evidence Remains Unclear – RPTH Journal
-
Jun 29, 2026, 20:09Mamta Soni: The Role of Anti-Xa Monitoring in Anticoagulation Management